Skip to main content
Erschienen in: Journal of Neural Transmission 5/2020

18.01.2020 | Neurology and Preclinical Neurological Studies - Review Article

Treatment of tics associated with Tourette syndrome

verfasst von: Joseph Jankovic

Erschienen in: Journal of Neural Transmission | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Motor and phonic tics associated with Tourette syndrome (TS) can range in severity from barely perceptible to disabling and most patients have a variety of behavioral co-morbidities, particularly, attention deficit disorder and obsessive compulsive disorder. Therefore, therapy must be tailored to the individual needs of the patients. In addition to behavioral therapy, oral medications such as alpha agonists, dopamine depletors, anti-psychotics, and topiramate are used to control the involuntary movements and noises. Botulinum toxin injections are particularly effective in patients with troublesome focal motor and phonic tics, including coprolalia. Deep brain stimulation may be considered for patients with “malignant” TS, that is, refractory to medical therapy. When appropriate therapy is selected and implemented, most patients with TS can achieve their full potential and lead essentially normal life.
Literatur
Zurück zum Zitat Bellows S, Jankovic J (2020) Treatment of dystonia and tics. Clin Parkinsonism Relat Disord 2:12–19 Bellows S, Jankovic J (2020) Treatment of dystonia and tics. Clin Parkinsonism Relat Disord 2:12–19
Zurück zum Zitat Bashir H, Jankovic J (2018) Deutetrabenazine for the treatment of Huntington’s chorea. Expert Rev Neurother 18(8):625–631PubMed Bashir H, Jankovic J (2018) Deutetrabenazine for the treatment of Huntington’s chorea. Expert Rev Neurother 18(8):625–631PubMed
Zurück zum Zitat Black KJ, Jankovic J, Hershey T, McNaught KS, Mink JW, Walkup J (2014) Progress in research on Tourette syndrome. J Obsessive Compuls Relat Disord 3(4):359–362PubMedPubMedCentral Black KJ, Jankovic J, Hershey T, McNaught KS, Mink JW, Walkup J (2014) Progress in research on Tourette syndrome. J Obsessive Compuls Relat Disord 3(4):359–362PubMedPubMedCentral
Zurück zum Zitat Black N, Stockings E, Campbell G, Tran LT, Zagic D, Hall WD, Farrell M, Degenhardt L (2019) Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiat 6(12):995–1010 Black N, Stockings E, Campbell G, Tran LT, Zagic D, Hall WD, Farrell M, Degenhardt L (2019) Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiat 6(12):995–1010
Zurück zum Zitat Brander G, Isomura K, Chang Z, Kuja-Halkola R, Almqvist C, Larsson H, Mataix-Cols D, Fernández de la Cruz L (2019) Association of Tourette syndrome and chronic tic disorder with metabolic and cardiovascular disorders. JAMA Neurol 76(4):454–461PubMedPubMedCentral Brander G, Isomura K, Chang Z, Kuja-Halkola R, Almqvist C, Larsson H, Mataix-Cols D, Fernández de la Cruz L (2019) Association of Tourette syndrome and chronic tic disorder with metabolic and cardiovascular disorders. JAMA Neurol 76(4):454–461PubMedPubMedCentral
Zurück zum Zitat Carbon M, Kane JM, Leucht S, Correll CU (2018) Tardive dyskinesia risk with first-and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry 17(3):330–340PubMedPubMedCentral Carbon M, Kane JM, Leucht S, Correll CU (2018) Tardive dyskinesia risk with first-and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry 17(3):330–340PubMedPubMedCentral
Zurück zum Zitat Cavanna AE, Nani A (2013) Antiepileptic drugs and Tourette syndrome. Int Rev Neurobiol 112:373–389PubMed Cavanna AE, Nani A (2013) Antiepileptic drugs and Tourette syndrome. Int Rev Neurobiol 112:373–389PubMed
Zurück zum Zitat Chen JJ, Ondo WG, Dashtipour K, Swope DM (2012) Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clin Ther 34(7):1487–1504PubMed Chen JJ, Ondo WG, Dashtipour K, Swope DM (2012) Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clin Ther 34(7):1487–1504PubMed
Zurück zum Zitat Cheung MY, Shahed J, Jankovic J (2007) Malignant Tourette syndrome. Mov Disord 22(12):1743–1750PubMed Cheung MY, Shahed J, Jankovic J (2007) Malignant Tourette syndrome. Mov Disord 22(12):1743–1750PubMed
Zurück zum Zitat Coulombe MA, Elkaim LM, Alotaibi NM et al (2018) Deep brain stimulation for Gilles de la Tourette syndrome in children and youth: a meta-analysis with individual participant data. J Neurosurg Pediatr 23(2):236–246PubMed Coulombe MA, Elkaim LM, Alotaibi NM et al (2018) Deep brain stimulation for Gilles de la Tourette syndrome in children and youth: a meta-analysis with individual participant data. J Neurosurg Pediatr 23(2):236–246PubMed
Zurück zum Zitat Curtis A, Clarke CE, Rickards HE (2009) Cannabinoids for Tourette’s syndrome. Cochrane Database Syst Rev 4:CD006565 Curtis A, Clarke CE, Rickards HE (2009) Cannabinoids for Tourette’s syndrome. Cochrane Database Syst Rev 4:CD006565
Zurück zum Zitat Draper A, Stephenson MC, Jackson GM, Pépés S, Morgan PS, Morris PG, Jackson SR (2014) Increased GABA contributes to enhanced control over motor excitability in Tourette syndrome. Curr Biol 24(19):2343–2347PubMedPubMedCentral Draper A, Stephenson MC, Jackson GM, Pépés S, Morgan PS, Morris PG, Jackson SR (2014) Increased GABA contributes to enhanced control over motor excitability in Tourette syndrome. Curr Biol 24(19):2343–2347PubMedPubMedCentral
Zurück zum Zitat Du YS, Li HF, Vance A, Zhong YQ, Jiao FY, Wang HM, Wang MJ, Su LY, Yu DL, Ma SW, Wu JB (2008) Randomized double-blind multicentre placebo-controlled clinical trial of the clonidine adhesive patch for the treatment of tic disorders. Aust N Z J Psychiatry 42(9):807–813PubMed Du YS, Li HF, Vance A, Zhong YQ, Jiao FY, Wang HM, Wang MJ, Su LY, Yu DL, Ma SW, Wu JB (2008) Randomized double-blind multicentre placebo-controlled clinical trial of the clonidine adhesive patch for the treatment of tic disorders. Aust N Z J Psychiatry 42(9):807–813PubMed
Zurück zum Zitat Gilbert DL, Budman CL, Singer HS, Kurlan R, Chipkin RE (2014) A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome. Clin Neuropharmacol 37(1):26–30PubMed Gilbert DL, Budman CL, Singer HS, Kurlan R, Chipkin RE (2014) A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome. Clin Neuropharmacol 37(1):26–30PubMed
Zurück zum Zitat Gilbert DL, Murphy TK, Jankovic J, Budman CL, Black KJ, Kurlan RM, Coffman KA, McCracken JT, Juncos J, Grant JE, Chipkin RE (2018) Ecopipam, a D1 receptor antagonist, for treatment of tourette syndrome in children: a randomized, placebo-controlled crossover study. Mov Disord 33(8):1272–1280PubMed Gilbert DL, Murphy TK, Jankovic J, Budman CL, Black KJ, Kurlan RM, Coffman KA, McCracken JT, Juncos J, Grant JE, Chipkin RE (2018) Ecopipam, a D1 receptor antagonist, for treatment of tourette syndrome in children: a randomized, placebo-controlled crossover study. Mov Disord 33(8):1272–1280PubMed
Zurück zum Zitat Godar SC, Mosher LJ, Strathman HJ et al (2016) The D1CT-7 mouse model of Tourette syndrome displays sensorimotor gating deficits in response to spatial confinement. Br J Pharmacol 173(13):2111–2121PubMed Godar SC, Mosher LJ, Strathman HJ et al (2016) The D1CT-7 mouse model of Tourette syndrome displays sensorimotor gating deficits in response to spatial confinement. Br J Pharmacol 173(13):2111–2121PubMed
Zurück zum Zitat Hedderick EF, Morris CM, Singer HS (2009) Double-blind, crossover study of clonidine and levetiracetam in Tourette syndrome. Pediatr Neurol 40(6):420–425PubMed Hedderick EF, Morris CM, Singer HS (2009) Double-blind, crossover study of clonidine and levetiracetam in Tourette syndrome. Pediatr Neurol 40(6):420–425PubMed
Zurück zum Zitat Jankovic J (2015) Therapeutic developments for tics and myoclonus. Mov Disord 30(11):1566–1573PubMed Jankovic J (2015) Therapeutic developments for tics and myoclonus. Mov Disord 30(11):1566–1573PubMed
Zurück zum Zitat Jankovic J (2016) Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother 17(18):2461–2470PubMed Jankovic J (2016) Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother 17(18):2461–2470PubMed
Zurück zum Zitat Jankovic J (2018) An update on new and unique uses of botulinum toxin in movement disorders. Toxicon 1(147):84–88 Jankovic J (2018) An update on new and unique uses of botulinum toxin in movement disorders. Toxicon 1(147):84–88
Zurück zum Zitat Jankovic J, Jimenez-Shahed J, Brown LW (2010) A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry 81(1):70–73PubMed Jankovic J, Jimenez-Shahed J, Brown LW (2010) A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry 81(1):70–73PubMed
Zurück zum Zitat Jankovic J, Jimenez-Shahed J, Budman C, Coffey B, Murphy T, Shprecher D, Stamler D (2016) Deutetrabenazine in tics associated with Tourette syndrome. Tremor Other Hyperkinet Mov (NY) 7(6):422 Jankovic J, Jimenez-Shahed J, Budman C, Coffey B, Murphy T, Shprecher D, Stamler D (2016) Deutetrabenazine in tics associated with Tourette syndrome. Tremor Other Hyperkinet Mov (NY) 7(6):422
Zurück zum Zitat Jiang M, van der Stelt M (2018) Activity-based protein profiling delivers selective drug candidate ABX-1431, a monoacylglycerol lipase inhibitor, to control lipid metabolism in neurological disorders. J Med Chem 61(20):9059–9061PubMedPubMedCentral Jiang M, van der Stelt M (2018) Activity-based protein profiling delivers selective drug candidate ABX-1431, a monoacylglycerol lipase inhibitor, to control lipid metabolism in neurological disorders. J Med Chem 61(20):9059–9061PubMedPubMedCentral
Zurück zum Zitat Kefalopoulou Z, Zrinzo L, Jahanshahi M et al (2015) Bilateral globus pallidus stimulation for severe Tourette’s syndrome: a double-blind, randomised crossover trial. Lancet Neurol 14(6):595–605PubMed Kefalopoulou Z, Zrinzo L, Jahanshahi M et al (2015) Bilateral globus pallidus stimulation for severe Tourette’s syndrome: a double-blind, randomised crossover trial. Lancet Neurol 14(6):595–605PubMed
Zurück zum Zitat Kenney C, Hunter C, Mejia N, Jankovic J (2007) Tetrabenazine in the treatment of Tourette syndrome. J Ped Neurol 5:9–13 Kenney C, Hunter C, Mejia N, Jankovic J (2007) Tetrabenazine in the treatment of Tourette syndrome. J Ped Neurol 5:9–13
Zurück zum Zitat Kim DD, Barr AM, Chung Y et al (2018) Antipsychotic-associated symptoms of Tourette syndrome: a systematic review. CNS Drugs 32(10):917–938PubMed Kim DD, Barr AM, Chung Y et al (2018) Antipsychotic-associated symptoms of Tourette syndrome: a systematic review. CNS Drugs 32(10):917–938PubMed
Zurück zum Zitat Kluger B, Triolo P, Jones W, Jankovic J (2015) The therapeutic potential of cannabinoids for movement disorders. Mov Disord 30(3):313–327PubMedPubMedCentral Kluger B, Triolo P, Jones W, Jankovic J (2015) The therapeutic potential of cannabinoids for movement disorders. Mov Disord 30(3):313–327PubMedPubMedCentral
Zurück zum Zitat Krack P, Volkmann J, Tinkhauser G, Deuschl G (2019) Deep brain stimulation in movement disorders: from experimental surgery to evidence-based therapy. Mov Disord 34(12):1795–1810PubMed Krack P, Volkmann J, Tinkhauser G, Deuschl G (2019) Deep brain stimulation in movement disorders: from experimental surgery to evidence-based therapy. Mov Disord 34(12):1795–1810PubMed
Zurück zum Zitat Krauss JK, Jankovic J (1996) Severe motor tics causing cervical myelopathy in Tourette’s syndrome. Mov Disord 11(5):563–566PubMed Krauss JK, Jankovic J (1996) Severe motor tics causing cervical myelopathy in Tourette’s syndrome. Mov Disord 11(5):563–566PubMed
Zurück zum Zitat Kwak CH, Hanna PA, Jankovic J (2000) Botulinum toxin in the treatment of tics. Arch Neurol 57(8):1190–1193PubMed Kwak CH, Hanna PA, Jankovic J (2000) Botulinum toxin in the treatment of tics. Arch Neurol 57(8):1190–1193PubMed
Zurück zum Zitat Kwak C, Dat Vuong K, Jankovic J (2003) Premonitory sensory phenomenon in Tourette’s syndrome. Mov Disord 18(12):1530–1533PubMed Kwak C, Dat Vuong K, Jankovic J (2003) Premonitory sensory phenomenon in Tourette’s syndrome. Mov Disord 18(12):1530–1533PubMed
Zurück zum Zitat Lerner A, Bagic A, Simmons JM et al (2012) Widespread abnormality of the γ-aminobutyric acid-ergic system in Tourette syndrome. Brain 135(Pt 6):1926–1936PubMedPubMedCentral Lerner A, Bagic A, Simmons JM et al (2012) Widespread abnormality of the γ-aminobutyric acid-ergic system in Tourette syndrome. Brain 135(Pt 6):1926–1936PubMedPubMedCentral
Zurück zum Zitat Lim K, See YM, Lee J (2017) A systematic review of the effectiveness of medical cannabis for psychiatric, movement and neurodegenerative disorders. Clin Psychopharmacol Neurosci 15(4):301–312PubMedPubMedCentral Lim K, See YM, Lee J (2017) A systematic review of the effectiveness of medical cannabis for psychiatric, movement and neurodegenerative disorders. Clin Psychopharmacol Neurosci 15(4):301–312PubMedPubMedCentral
Zurück zum Zitat Lotia M, Jankovic J (2016) Botulinum Toxin for the Treatment of Tremor and Tics. Semin Neurol 36(1):54–63PubMed Lotia M, Jankovic J (2016) Botulinum Toxin for the Treatment of Tremor and Tics. Semin Neurol 36(1):54–63PubMed
Zurück zum Zitat Marras C, Andrews D, Sime E, Lang AE (2001) Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial. Neurology 56(5):605–610PubMed Marras C, Andrews D, Sime E, Lang AE (2001) Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial. Neurology 56(5):605–610PubMed
Zurück zum Zitat Martinez-Ramirez D, Jimenez-Shahed J, Leckman JF et al (2018) Efficacy and safety of deep brain stimulation in tourette syndrome: the international tourette syndrome deep brain stimulation public database and registry. JAMA Neurol 75(3):353–359PubMedPubMedCentral Martinez-Ramirez D, Jimenez-Shahed J, Leckman JF et al (2018) Efficacy and safety of deep brain stimulation in tourette syndrome: the international tourette syndrome deep brain stimulation public database and registry. JAMA Neurol 75(3):353–359PubMedPubMedCentral
Zurück zum Zitat Mogwitz S, Buse J, Ehrlich S, Roessner V (2013) Clinical pharmacology of dopamine-modulating agents in Tourette’s syndrome. Int Rev Neurobiol 112:281–349PubMed Mogwitz S, Buse J, Ehrlich S, Roessner V (2013) Clinical pharmacology of dopamine-modulating agents in Tourette’s syndrome. Int Rev Neurobiol 112:281–349PubMed
Zurück zum Zitat Müller-Vahl KR, Szejko N, Wilke F, Jakubovski E, Geworski L, Bengel F, Berding G (2019) Serotonin transporter binding is increased in Tourette syndrome with Obsessive Compulsive Disorder. Sci Rep 9(1):972PubMedPubMedCentral Müller-Vahl KR, Szejko N, Wilke F, Jakubovski E, Geworski L, Bengel F, Berding G (2019) Serotonin transporter binding is increased in Tourette syndrome with Obsessive Compulsive Disorder. Sci Rep 9(1):972PubMedPubMedCentral
Zurück zum Zitat Murphy TK, Fernandez TV, Coffey BJ, Rahman O, Gavaletz A, Hanks CE, Tillberg CS, Gomez LI, Sukhodolsky DG, Katsovich L, Scahill L (2017) Extended-release guanfacine does not show a large effect on tic severity in children with chronic tic disorders. J Child Adolesc Psychopharmacol 27(9):762–770PubMed Murphy TK, Fernandez TV, Coffey BJ, Rahman O, Gavaletz A, Hanks CE, Tillberg CS, Gomez LI, Sukhodolsky DG, Katsovich L, Scahill L (2017) Extended-release guanfacine does not show a large effect on tic severity in children with chronic tic disorders. J Child Adolesc Psychopharmacol 27(9):762–770PubMed
Zurück zum Zitat Niemann N, Jankovic J (2018) Treatment of tardive dyskinesia: a general overview with focus on the vesicular monoamine transporter 2 inhibitors. Drugs 78(5):525–541PubMed Niemann N, Jankovic J (2018) Treatment of tardive dyskinesia: a general overview with focus on the vesicular monoamine transporter 2 inhibitors. Drugs 78(5):525–541PubMed
Zurück zum Zitat Pandey S, Dash D (2019) Progress in Pharmacological and surgical management of Tourette syndrome and other chronic Tic disorders. Neurologist 24(3):93–108PubMed Pandey S, Dash D (2019) Progress in Pharmacological and surgical management of Tourette syndrome and other chronic Tic disorders. Neurologist 24(3):93–108PubMed
Zurück zum Zitat Pandey S, Srivanitchapoom P, Kirubakaran R, Berman BD (2018) Botulinum toxin for motor and phonic tics in Tourette’s syndrome. Cochrane Database Syst Rev 1:CD012285PubMed Pandey S, Srivanitchapoom P, Kirubakaran R, Berman BD (2018) Botulinum toxin for motor and phonic tics in Tourette’s syndrome. Cochrane Database Syst Rev 1:CD012285PubMed
Zurück zum Zitat Paschou P, Fernandez TV, Sharp F, Heiman GA, Hoekstra PJ (2013) Genetic susceptibility and neurotransmitters in Tourette syndrome. Int Rev Neurobiol 112:155–177PubMedPubMedCentral Paschou P, Fernandez TV, Sharp F, Heiman GA, Hoekstra PJ (2013) Genetic susceptibility and neurotransmitters in Tourette syndrome. Int Rev Neurobiol 112:155–177PubMedPubMedCentral
Zurück zum Zitat Peña MS, Yaltho TC, Jankovic J (2011) Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord 26(1):147–152PubMed Peña MS, Yaltho TC, Jankovic J (2011) Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord 26(1):147–152PubMed
Zurück zum Zitat Porta M, Maggioni G, Ottaviani F, Schindler A (2004) Treatment of phonic tics in patients with Tourette’s syndrome using botulinum toxin type A. Neurol Sci 24(6):420–423PubMed Porta M, Maggioni G, Ottaviani F, Schindler A (2004) Treatment of phonic tics in patients with Tourette’s syndrome using botulinum toxin type A. Neurol Sci 24(6):420–423PubMed
Zurück zum Zitat Pringsheim T, Holler-Managan Y, Okun MS, Jankovic J, Piacentini J, Cavanna AE, Martino D, Müller-Vahl K, Woods DW, Robinson M, Jarvie E, Roessner V, Oskoui M (2019a) Comprehensive systematic review summary: treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology 92(19):907–915PubMedPubMedCentral Pringsheim T, Holler-Managan Y, Okun MS, Jankovic J, Piacentini J, Cavanna AE, Martino D, Müller-Vahl K, Woods DW, Robinson M, Jarvie E, Roessner V, Oskoui M (2019a) Comprehensive systematic review summary: treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology 92(19):907–915PubMedPubMedCentral
Zurück zum Zitat Pringsheim T, Okun MS, Müller-Vahl K, Martino D, Jankovic J, Cavanna AE, Woods DW, Robinson M, Jarvie E, Roessner V, Oskoui M, Holler-Managan Y, Piacentini J (2019b) Practice guideline recommendations summary: treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology 92(19):896–906PubMedPubMedCentral Pringsheim T, Okun MS, Müller-Vahl K, Martino D, Jankovic J, Cavanna AE, Woods DW, Robinson M, Jarvie E, Roessner V, Oskoui M, Holler-Managan Y, Piacentini J (2019b) Practice guideline recommendations summary: treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology 92(19):896–906PubMedPubMedCentral
Zurück zum Zitat Quezada J, Coffman KA (2018) Current approaches and new developments in the pharmacological management of tourette syndrome. CNS Drugs 32(1):33–45PubMedPubMedCentral Quezada J, Coffman KA (2018) Current approaches and new developments in the pharmacological management of tourette syndrome. CNS Drugs 32(1):33–45PubMedPubMedCentral
Zurück zum Zitat Rizzo R, Pellico A, Silvestri PR et al (2018) A randomized controlled trial comparing behavioral, educational, and pharmacological treatments in youths with chronic Tic disorder or Tourette syndrome. Front Psychiatry 9:100PubMedPubMedCentral Rizzo R, Pellico A, Silvestri PR et al (2018) A randomized controlled trial comparing behavioral, educational, and pharmacological treatments in youths with chronic Tic disorder or Tourette syndrome. Front Psychiatry 9:100PubMedPubMedCentral
Zurück zum Zitat Robertson MM, Eapen V, Singer HS, Martino D, Scharf JM, Paschou P, Roessner V, Woods DW, Hariz M, Mathews CA, Črnčec R, Leckman JF (2017) Gilles de la Tourette syndrome. Nat Rev Dis Prime 3:16097 Robertson MM, Eapen V, Singer HS, Martino D, Scharf JM, Paschou P, Roessner V, Woods DW, Hariz M, Mathews CA, Črnčec R, Leckman JF (2017) Gilles de la Tourette syndrome. Nat Rev Dis Prime 3:16097
Zurück zum Zitat Roessner V, Schoenefeld K, Buse J, Bender S, Ehrlich S, Münchau A (2013) Pharmacological treatment of tic disorders and Tourette Syndrome. Neuropharmacology 68:143–149PubMed Roessner V, Schoenefeld K, Buse J, Bender S, Ehrlich S, Münchau A (2013) Pharmacological treatment of tic disorders and Tourette Syndrome. Neuropharmacology 68:143–149PubMed
Zurück zum Zitat Sahli ZT, Tarazi FI (2018) Pimavanserin: novel pharmacotherapy for Parkinson’s disease psychosis. Expert Opin Drug Discov 13:103–110PubMed Sahli ZT, Tarazi FI (2018) Pimavanserin: novel pharmacotherapy for Parkinson’s disease psychosis. Expert Opin Drug Discov 13:103–110PubMed
Zurück zum Zitat Sallee F, Kohegyi E, Zhao J, McQuade R, Cox K, Sanchez R, van Beek A, Nyilas M, Carson W, Kurlan R (2017) Randomized, double-blind, placebo-controlled trial demonstrates the efficacy and safety of oral aripiprazole for the treatment of Tourette’s disorder in children and adolescents. J Child Adolesc Psychopharmacol 27(9):771–781PubMedPubMedCentral Sallee F, Kohegyi E, Zhao J, McQuade R, Cox K, Sanchez R, van Beek A, Nyilas M, Carson W, Kurlan R (2017) Randomized, double-blind, placebo-controlled trial demonstrates the efficacy and safety of oral aripiprazole for the treatment of Tourette’s disorder in children and adolescents. J Child Adolesc Psychopharmacol 27(9):771–781PubMedPubMedCentral
Zurück zum Zitat Santangelo A, Bortolato M, Mosher LJ, Crescimanno G, Di Giovanni G, Cassioli E, Ricca V, Casarrubea M (2018) Behavioral fragmentation in the D1CT-7 mouse model of Tourette’s syndrome. CNS Neurosci Ther 24(8):703–711PubMedPubMedCentral Santangelo A, Bortolato M, Mosher LJ, Crescimanno G, Di Giovanni G, Cassioli E, Ricca V, Casarrubea M (2018) Behavioral fragmentation in the D1CT-7 mouse model of Tourette’s syndrome. CNS Neurosci Ther 24(8):703–711PubMedPubMedCentral
Zurück zum Zitat Schultz JL, Killoran A, Nopoulos PC, Chabal CC, Moser DJ, Kamholz JA (2018) Evaluating depression and suicidality in tetrabenazine users with Huntington disease. Neurology 91(3):e202–e207PubMed Schultz JL, Killoran A, Nopoulos PC, Chabal CC, Moser DJ, Kamholz JA (2018) Evaluating depression and suicidality in tetrabenazine users with Huntington disease. Neurology 91(3):e202–e207PubMed
Zurück zum Zitat Scott BL, Jankovic J, Donovan DT (1996) Botulinum toxin injection into vocal cord in the treatment of malignant coprolalia associated with Tourette’s syndrome. Mov Disord 11(4):431–433PubMed Scott BL, Jankovic J, Donovan DT (1996) Botulinum toxin injection into vocal cord in the treatment of malignant coprolalia associated with Tourette’s syndrome. Mov Disord 11(4):431–433PubMed
Zurück zum Zitat Toren P, Weizman A, Ratner S, Cohen D, Laor N (2005) Ondansetron treatment in Tourette’s disorder: a 3-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 66(4):499–503PubMed Toren P, Weizman A, Ratner S, Cohen D, Laor N (2005) Ondansetron treatment in Tourette’s disorder: a 3-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 66(4):499–503PubMed
Zurück zum Zitat Tourette’s Syndrome Study Group (2002) Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 58(4):527–536 Tourette’s Syndrome Study Group (2002) Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 58(4):527–536
Zurück zum Zitat Viswanathan A, Jimenez-Shahed J, Baizabal Carvallo JF, Jankovic J (2012) Deep brain stimulation for Tourette syndrome: target selection. Stereotact Funct Neurosurg 90(4):213–224PubMed Viswanathan A, Jimenez-Shahed J, Baizabal Carvallo JF, Jankovic J (2012) Deep brain stimulation for Tourette syndrome: target selection. Stereotact Funct Neurosurg 90(4):213–224PubMed
Zurück zum Zitat Weisman H, Qureshi IA, Leckman JF, Scahill L, Bloch MH (2013) Systematic review: pharmacological treatment of tic disorders–efficacy of antipsychotic and alpha-2 adrenergic agonist agents. Neurosci Biobehav Rev 37(6):1162–1171PubMed Weisman H, Qureshi IA, Leckman JF, Scahill L, Bloch MH (2013) Systematic review: pharmacological treatment of tic disorders–efficacy of antipsychotic and alpha-2 adrenergic agonist agents. Neurosci Biobehav Rev 37(6):1162–1171PubMed
Zurück zum Zitat Wijemanne S, Wu LJ, Jankovic J (2014) Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome. Mov Disord 29(1):126–130PubMed Wijemanne S, Wu LJ, Jankovic J (2014) Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome. Mov Disord 29(1):126–130PubMed
Zurück zum Zitat Yang CS, Zhang LL, Zeng LN, Huang L, Liu YT (2013) Topiramate for Tourette’s syndrome in children: a meta-analysis. Pediatr Neurol 49(5):344–350PubMed Yang CS, Zhang LL, Zeng LN, Huang L, Liu YT (2013) Topiramate for Tourette’s syndrome in children: a meta-analysis. Pediatr Neurol 49(5):344–350PubMed
Zurück zum Zitat Yoo HK, Joung YS, Lee JS, Song DH, Lee YS, Kim JW, Kim BN, Cho SC (2013) A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette’s disorder. J Clin Psychiatry 74(8):e772–e780PubMed Yoo HK, Joung YS, Lee JS, Song DH, Lee YS, Kim JW, Kim BN, Cho SC (2013) A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette’s disorder. J Clin Psychiatry 74(8):e772–e780PubMed
Metadaten
Titel
Treatment of tics associated with Tourette syndrome
verfasst von
Joseph Jankovic
Publikationsdatum
18.01.2020
Verlag
Springer Vienna
Erschienen in
Journal of Neural Transmission / Ausgabe 5/2020
Print ISSN: 0300-9564
Elektronische ISSN: 1435-1463
DOI
https://doi.org/10.1007/s00702-019-02105-w

Weitere Artikel der Ausgabe 5/2020

Journal of Neural Transmission 5/2020 Zur Ausgabe

Neurology and Preclinical Neurological Studies - Review Article

Parkinson’s disease treatment: past, present, and future

Neurology and Preclinical Neurological Studies - Review Article

Neuroprotection in Parkinson’s disease: facts and hopes

Neurology and Preclinical Neurological Studies - Review Article

Non-pharmacological management of cognitive impairment in Parkinson’s disease

Neurology and Preclinical Neurological Studies - Original Article

Creation of a gene expression classifier for predicting Parkinson’s disease rate of progression

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.